What is the most effective systemic treatment for tinea corporis?

Systemic Treatment for Tinea Corporis

For systemic treatment of tinea corporis, terbinafine and itraconazole are equally effective first-line options, with terbinafine preferred for Trichophyton species and itraconazole offering broader coverage including Microsporum species.

When Systemic Therapy is Indicated

Systemic antifungal treatment is necessary when 1:

• Lesions are multiple or extensive
• Deep tissue involvement
• Recurrent or chronic infection
• Unresponsive to topical therapy
• Patient is immunocompromised

First-Line Systemic Options

Terbinafine

• Dosing by weight:

  • <20 kg: 62.5 mg daily for 2-4 weeks
  • 20-40 kg: 125 mg daily for 2-4 weeks

  • 40 kg: 250 mg daily for 2-4 weeks 2

• Advantages: Fungicidal action, shorter treatment duration (improves compliance), well-tolerated, inexpensive 3

• Best for: Trichophyton species (T. rubrum, T. tonsurans, T. violaceum) 2, 4

• Limitations: Less effective against Microsporum species 2

Itraconazole

• Dosing: 100 mg daily for 15 days 5 or 50-100 mg daily for 4 weeks, or 5 mg/kg/day for 2-4 weeks 2
• Advantages: Effective against both Trichophyton AND Microsporum species, pulsed regimens possible, available in liquid form 2
• Evidence: 100% mycological cure rate demonstrated in clinical studies 5
• Equally effective as terbinafine for tinea corporis and tinea cruris 4

Treatment Algorithm

1. Identify causative organism (if possible via culture) to guide therapy 2

   • If Trichophyton suspected/confirmed → Terbinafine
   • If Microsporum suspected/confirmed → Itraconazole or griseofulvin
   • If organism unknown → Either terbinafine or itraconazole acceptable

2. Monitor for treatment failure at 2-4 weeks:

   • Consider non-compliance, poor drug absorption, organism resistance, or reinfection 2
   • If clinical improvement but positive mycology → continue current therapy 2-4 more weeks
   • If no clinical improvement → switch to second-line agent

3. Second-line therapy:

   • If terbinafine failed → switch to itraconazole
   • If itraconazole failed → switch to terbinafine 2

Critical Pitfalls to Avoid

⚠️ Avoid combination antifungal-corticosteroid products - used in 7-10% of cases but promotes resistance and worsens outcomes 6, 3

⚠️ Emerging resistance concerns: T. indotineae (terbinafine-resistant) and T. mentagrophytes genotype VII are increasing globally 4. Consider culture and susceptibility testing for:

• Severe infections
• Treatment failures
• Widespread disease 1

⚠️ Diagnostic testing is underutilized - only <10% of patients receive confirmatory testing 6. KOH preparation or fungal culture should be performed when diagnosis is uncertain or infection is severe/resistant 1

Drug Interactions & Contraindications

Terbinafine: Minimal drug interactions, well-tolerated profile 4

Itraconazole: Significant interactions with 2:

• Warfarin (enhanced toxicity)
• Antihistamines (terfenadine, astemizole)
• Statins (simvastatin - myopathy risk)
• Decreased efficacy with H2 blockers, phenytoin, rifampicin

Treatment Endpoint

Mycological cure is the endpoint, not just clinical improvement 2. Repeat mycology sampling recommended until clearance achieved, as 63% of patients may still test positive despite clinical improvement 7.